tiprankstipranks
Medicenna Therapeutics Corp (TSE:MDNA)
TSX:MDNA

Medicenna Therapeutics Corp (MDNA) Stock Forecast & Price Target

163 Followers
See the Price Targets and Ratings of:

MDNA Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Medicenna
Therapeutics Corp
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MDNA Stock 12 Month Forecast

There Are No Analyst Ratings for TSE:MDNA In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

MDNA Financial Forecast

MDNA Earnings Forecast

Next quarter’s earnings estimate for MDNA is -C$0.06 with a range of -C$0.07 to -C$0.04. The previous quarter’s EPS was -C$0.15. MDNA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.61% of the time in the same period. In the last calendar year MDNA has Outperformed its overall industry.
Next quarter’s earnings estimate for MDNA is -C$0.06 with a range of -C$0.07 to -C$0.04. The previous quarter’s EPS was -C$0.15. MDNA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.61% of the time in the same period. In the last calendar year MDNA has Outperformed its overall industry.
No data currently available

MDNA Sales Forecast

Next quarter’s sales forecast for MDNA is C$0.00 with a range of C$0.00 to C$0.00. The previous quarter’s sales results were C$0.00. MDNA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 53.71% of the time in the same period. In the last calendar year MDNA has Underperformed its overall industry.
Next quarter’s sales forecast for MDNA is C$0.00 with a range of C$0.00 to C$0.00. The previous quarter’s sales results were C$0.00. MDNA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 53.71% of the time in the same period. In the last calendar year MDNA has Underperformed its overall industry.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bloom Burton
C$8.18
Buy
282.47%
Upside
Reiterated
04/10/24
We expect that cash of 31 should be sufficient to fund operations into 2Q-2025. Rating: BUY Target: Outstanding (MM) 69.6 Market Cap. (MM) C$105.8 Cash per share C$0.31 Avg. Report is priced as of prior trading close. All values in CAD unless otherwise noted.
H.C. Wainwright
C$3.41
Buy
59.36%
Upside
Reiterated
04/10/24
JonesTrading
C$5
Buy
133.64%
Upside
Reiterated
04/10/24
Medicenna reported MDNA11 monotherapy dose escalation and dose expansion data at AACR ( press release ). There was an additional PR, bringing the total number of clinical responses up to n=3 PRs and n=1 iPR across dose escalation and expansion. In Ph2 eligible patients receiving ≥60 ug/kg, ORR was 29% (4/14). In the expansion arm, ORR per RECIST was 25% (1/4) and ORR per iRECIST was 50% (2/4).
Research Capital
C$2.18
Buy
1.99%
Upside
Reiterated
02/14/24
MDNA is undervalued, Research Capital saysBy Nick Waddell Published on February 15, 2024 Last Updated on February 15, 2024 Filed under: All posts , Analysts , Life Sciences Stock: mdnaMDNA is undervalued, Research Capital says
Oppenheimer
C$10.91C$4.09
Buy
91.24%
Upside
Reiterated
08/14/23
Medicenna Therapeutics price target lowered to $3 from $8 at OppenheimerMedicenna Therapeutics price target lowered to $3 from $8 at Oppenheimer

Best Analysts Covering Medicenna Therapeutics Corp

Which Analyst Should I Follow If I Want to Buy TSE:MDNA and Sell After:
1 Month
Matthew BieglerOppenheimer
Success Rate
3/11 ratings generated profit
27%
Average Return
-6.99%
reiterated a buy rating 11 months ago
Copying Matthew Biegler's trades and holding each position for 1 Month would result in 27.27% of your transactions generating a profit, with an average return of -6.99% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Swayampakula RamakanthH.C. Wainwright
Success Rate
3/14 ratings generated profit
21%
Average Return
-18.57%
reiterated a buy rating 3 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 3 Months would result in 21.43% of your transactions generating a profit, with an average return of -18.57% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Swayampakula RamakanthH.C. Wainwright
Success Rate
4/14 ratings generated profit
29%
Average Return
+14.98%
reiterated a buy rating 3 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of +14.98% per trade.
2 Years
Swayampakula RamakanthH.C. Wainwright
Success Rate
10/14 ratings generated profit
71%
Average Return
+73.84%
reiterated a buy rating 3 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +73.84% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDNA Analyst Recommendation Trends

Rating
Aug 23
Oct 23
Nov 23
Feb 24
Apr 24
Strong Buy
5
5
6
4
5
Buy
0
0
0
0
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
5
6
4
6
In the current month, MDNA has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MDNA average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

MDNA Stock Forecast FAQ

What is TSE:MDNA’s average 12-month price target, according to analysts?
Currently, no data Available
What is TSE:MDNA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for TSE:MDNA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is TSE:MDNA a Buy, Sell or Hold?
      Currently, no data Available
      What is Medicenna Therapeutics Corp’s price target?
      Currently, no data Available
      What do analysts say about Medicenna Therapeutics Corp?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of TSE:MDNA?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis